Month: October 2016

ER vs. IR Drugs: An Interview with Theresa Cassidy, VP of Health Analytics

Inflexxion’s Vice President of Health Analytics, Theresa Cassidy, was recently interviewed on the issues and abuse of Extended Release (ER) opioids vs. Immediate Release (IR) opioids based on supporting data and analytics. Q1: Extended Release opioids have more stringent regulatory restrictions because of their potential for tampering/abuse. The focus on extended-release/long acting opioids as a class… Read more »

Recent Study: Progression of non-medical use of hydrocodone combination products: results from an Internet survey of recreational drug users

Earlier this year, Inflexxion and KemPharm Pharmaceuticals presented a poster at the International Conference on Opioids based on a recent study of non-medical use of prescription opioids.  According to SAMSHA, Non-medical use of prescription opioids continues to increase.  However, little is known about the potential impact commonly prescribed opioids, such as hydrocodone combination products (HCPs), have… Read more »

Inflexxion to provide data to FDA to evaluate opioid-related drug risks

Inflexxion, Inc. Awarded FDA Contract to Assist in Evaluation of Opioid-Related Drug Risks Inflexxion to provide analysis to the FDA from its surveillance data system on prescription drug abuse NEWTON, MA (October 17, 2016) – The US Food and Drug Administration (FDA) has awarded Inflexxion, Inc. a five-year, $10 million IDIQ contract.  The contract addresses,… Read more »